Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JZP898 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part A1 Dose Exploration: JZP898 monotherapy | EXPERIMENTAL | - |
| Part A2 Dose Exploration: JZP898 in combination with pembrolizumab | EXPERIMENTAL | - |
| Part B Combination Expansion: JZP898 in combination with pembrolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| JZP898 | DRUG | Investigational drug monotherapy |
| Pembrolizumab | DRUG | Anti-PD1 antibody |
Inclusion Criteria * Adult ≥ 18 years of age * Histological or cytological diagnosis of advanced or metastatic solid tumor. 1. Previously treated participants with solid tumors that are amenable to CPI therapy (eg. NSCLC, melanoma, HNSCC, RCC, HCC, gastroesophageal carcinomas, UC, or CRC \[MSI-H...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
JZP898 is an investigational small molecule being studied in adults with advanced or metastatic solid tumors. It is not approved for any indication and remains in Phase 1 clinical development. The trial enrolls patients with advanced solid tumor and metastatic solid tumor in the United States.
JZP898 targets interferon alpha 2b, a cytokine. It is a small molecule designed to act on this cytokine pathway. The Phase 1 study evaluates JZP898 as monotherapy and in combination with pembrolizumab in adults with advanced or metastatic solid tumors.
JZP898 is being developed by Jazz Pharmaceuticals plc, which trades on the Nasdaq under the ticker JAZZ. The company is the sponsor of the Phase 1 trial evaluating the drug in advanced solid tumors.
JZP898 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA for any indication. The ongoing Phase 1 trial is currently recruiting participants with advanced or metastatic solid tumors.
JZP898 is being studied in one active clinical trial, NCT06108050, titled JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors. The trial is Phase 1, recruiting, and plans to enroll 177 participants in the United States.